Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Mark Van Oene Biography and Net Worth

COO of Pacific Biosciences of California

Mark recently joined Pacific Biosciences in the newly created role of Chief Operating Officer where he will manage our research, development and manufacturing organizations and will be responsible for driving our strategic planning and corporate development activities

Mark joins the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees.

He joined Illumina in 2006 as a regional account manager in Illumina’s sales organization, and advanced rapidly taking on senior commercial leadership roles with ever increasing areas of responsibility, ultimately assuming the Chief Commercial Officer role in 2017. During his fifteen year tenure at Illumina, he was instrumental in scaling Illumina’s global commercial organization, representing the voice of their customers and driving significant annual revenue growth.

Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics.

He earned as B.S. in Biochemistry from Western University and was a Ph.D. candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.

What is Mark Van Oene's net worth?: The estimated net worth of Mark Van Oene is at least $2.81 million as of August 16th, 2024. Mr. Van Oene owns 1,630,815 shares of Pacific Biosciences of California stock worth more than $2,805,002 as of November 20th. This net worth evaluation does not reflect any other investments that Mr. Van Oene may own. Additionally, Mr. Van Oene receives an annual salary of $935,640.00 as COO at Pacific Biosciences of California. Learn More about Mark Van Oene's net worth.
How old is Mark Van Oene?: Mr. Van Oene is currently 51 years old. There are 6 older executives and no younger executives at Pacific Biosciences of California. The oldest executive at Pacific Biosciences of California is Dr. Denis Zaccarin Ph.D., Senior Vice President of Research & Development, who is 58 years old. Learn More on Mark Van Oene's age.
What is Mark Van Oene's salary?: As the COO of Pacific Biosciences of California, Inc., Mr. Van Oene earns $935,640.00 per year. The highest earning executive at Pacific Biosciences of California is Mr. Christian O. Henry M.B.A., President, CEO & Director, who commands a salary of $1,410,000.00 per year. Learn More on Mark Van Oene's salary.
How do I contact Mark Van Oene?: The corporate mailing address for Mr. Van Oene and other Pacific Biosciences of California executives is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. Pacific Biosciences of California can also be reached via phone at (650) 521-8000 and via email at [email protected]. Learn More on Mark Van Oene's contact information.
Has Mark Van Oene been buying or selling shares of Pacific Biosciences of California?: Mark Van Oene has not been actively trading shares of Pacific Biosciences of California in the last ninety days. Most recently, Oene Mark Van sold 38,011 shares of the business's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $1.66, for a transaction totalling $63,098.26. Following the completion of the sale, the insider now directly owns 1,630,815 shares of the company's stock, valued at $2,707,152.90. Learn More on Mark Van Oene's trading history.
Who are Pacific Biosciences of California's active insiders?: Pacific Biosciences of California's insider roster includes (Pres), William Ericson (Director), Peter Fromen (Insider), Susan Kim (CFO), Kathy Ordonez (Director), and Mark Van Oene (COO). Learn More on Pacific Biosciences of California's active insiders.
Are insiders buying or selling shares of Pacific Biosciences of California?: During the last year, Pacific Biosciences of California insiders bought shares 1 times. They purchased a total of 40,000 shares worth more than $176,000.00. During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 158,417 shares worth more than $776,160.97. The most recent insider tranaction occured on August, 19th when insider Jeff Eidel sold 26,760 shares worth more than $42,548.40. Insiders at Pacific Biosciences of California own 2.4% of the company. Learn More about insider trades at Pacific Biosciences of California.
Information on this page was last updated on 8/19/2024.

Mark Van Oene Insider Trading History at Pacific Biosciences of California

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/16/2024	Sell	38,011	$1.66	$63,098.26	1,630,815
2/16/2024	Sell	33,560	$5.96	$200,017.60	876,611
1/9/2024	Sell	31,012	$7.77	$240,963.24	910,171
1/10/2023	Sell	26,722	$9.53	$254,660.66	640,808
1/11/2022	Sell	41,480	$14.23	$590,260.40

Mark Van Oene Buying and Selling Activity at Pacific Biosciences of California

Pacific Biosciences of California Company Overview

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Today's Range

Now: $1.72

$1.65

$1.78

50 Day Range

MA: $1.91

$1.55

$2.65

2 Week Range

Now: $1.72

$1.16

$10.65

Volume

8,385,337 shs

Average Volume

12,212,016 shs

Market Capitalization

$471.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Mark Van Oene Biography and Net Worth

What is Mark Van Oene's net worth?

How old is Mark Van Oene?

What is Mark Van Oene's salary?

How do I contact Mark Van Oene?

Has Mark Van Oene been buying or selling shares of Pacific Biosciences of California?

Who are Pacific Biosciences of California's active insiders?

Are insiders buying or selling shares of Pacific Biosciences of California?